Results 11 to 20 of about 23,280 (257)

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease [PDF]

Clinical and Molecular Hepatology, 2018
Background/Aims Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases in recent years. The aim of this study was to evaluate the effects of sitagliptin with and without a synbiotic supplement in the treatment of ...
Saba Sayari, Hassan Neishaboori, Maryam Jameshorani   +2 more
doaj   +3 more sources

Efficacy and safety of sitagliptin treatment in older adults with moderately controlled type 2 diabetes: the STREAM study

Scientific Reports, 2023
Sitagliptin has been suggested as a treatment option for older adults with type 2 diabetes (T2D). However, no randomized controlled trial has been performed to evaluate the efficacy and safety of sitagliptin treatment in older Japanese patients with T2D.
Mototsugu Nagao, Jun Sasaki, Hitoshi Sugihara, Kyoko Tanimura-Inagaki, Taro Harada, Ichiro Sakuma, Shinichi Oikawa, STREAM Study Investigators   +7 more
doaj   +2 more sources

Exploring novel targets of sitagliptin for type 2 diabetes mellitus: Network pharmacology, molecular docking, molecular dynamics simulation, and SPR approaches

Frontiers in Endocrinology, 2023
BackgroundDiabetes has become a serious global public health problem. With the increasing prevalence of type 2 diabetes mellitus (T2DM), the incidence of complications of T2DM is also on the rise.
Jian-hong Qi, Pu-yu Chen, Ding-yuan Cai, Yi Wang, Yue-lei Wei, Su-ping He, Wei Zhou   +6 more
doaj   +2 more sources

Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease

Frontiers in Endocrinology, 2022
PurposeDipeptidyl peptidase-4 inhibitors (DPP-4I), key regulators of the actions of incretin hormones, exert anti-hyperglycemic effects in type 2 diabetes mellitus (T2DM) patients.
Xingchun Wang, Xingchun Wang, Bangfeng Zhao, Hang Sun, Hui You, Shen Qu, Shen Qu   +6 more
doaj   +2 more sources

An Effective Delivery System of Sitagliptin Using Optimized Mucoadhesive Nanoparticles

Applied Sciences, 2018
Sitagliptin (MK-0431), is a potent oral hypoglycemic drug that is used for treating type 2 diabetes mellitus. However, the short half-life of sitagliptin requires patients to take a high dose of 50 mg twice per day, and the fraction of sitagliptin ...
Afzal Haq Asif, Sree Harsha, Niranjan Hodalur Puttaswamy, Bandar E. Al-Dhubiab   +3 more
doaj   +2 more sources

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Frontiers in Medicine, 2022
The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg ...
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani   +13 more
doaj   +2 more sources

Sitagliptin ameliorates busulfan-induced pulmonary and testicular injury in rats through antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects

Scientific Reports, 2023
Busulfan (BUS) is an anticancer agent with serious adverse effects on various body organs, including the lung and testis. Sitagliptin was proven to have antioxidant, anti-inflammatory, antifibrotic, and antiapoptotic effects.
Eman A. Ali, Sara G. Tayel, Mona A. Abbas   +2 more
doaj   +2 more sources

Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells

Journal for ImmunoTherapy of Cancer
Background Dendritic cell (DC)-mediated antigen presentation is essential for the priming and activation of tumor-specific T cells. However, few drugs that specifically manipulate DC functions are available. The identification of drugs targeting DC holds
Zheng Huang, Jiaqi Zhang, Qi Peng, Lui Ng, Ian-Ian Ng, Tingzhong Tian, Kaimin Xiao, Xiyue Yao, Jianyang Zeng, Haidong Tang   +9 more
doaj   +2 more sources

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin

Diabetes, Metabolic Syndrome and Obesity, 2010
Bo AhrénDepartment of Clinical Sciences, Lund University, Lund, SwedenAbstract: Inhibition of dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagonlike peptide-1 (GLP-1). This increases circulating levels of active GLP-1, stimulates
Ahren B
doaj   +3 more sources

Hypoglycemia associated with off-label sitagliptin use

International Medical Case Reports Journal, 2008
Heather P Whitley1,2, Kristi Kelley11Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn, AL, USA; 2Department of Community and Rural Medicine, University of Alabama School of Medicine, Tuscaloosa, AL, USAPurpose: To ...
Heather P Whitley, Kristi Kelley
doaj   +1 more source